Trials / Completed
CompletedNCT01966003
Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
A Randomized, Double-blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 642 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to compare the effectiveness and safety of ABP 215 against bevacizumab in men and women with advanced non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carboplatin | Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W |
| DRUG | Paclitaxel | Administered 200 mg/m² IV Q3W |
| DRUG | ABP 215 | Administered 15 mg/kg Q3W by IV infusion |
| DRUG | Bevacizumab | Administered 15 mg/kg Q3W by IV infusion |
Timeline
- Start date
- 2013-11-11
- Primary completion
- 2015-07-23
- Completion
- 2015-07-23
- First posted
- 2013-10-21
- Last updated
- 2017-10-19
- Results posted
- 2017-10-19
Locations
4 sites across 3 countries: United States, Australia, Bulgaria
Source: ClinicalTrials.gov record NCT01966003. Inclusion in this directory is not an endorsement.